Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin

被引:418
作者
Hamano, Y
Zeisberg, M
Sugimoto, H
Lively, JC
Maeshima, Y
Yang, CQ
Hynes, RO
Werb, Z
Sudhakar, A
Kalluri, R [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Ctr Matrix Biol, Dept Med & Gastroenterol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] MIT, Ctr Canc Res, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA
[4] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
关键词
D O I
10.1016/S1535-6108(03)00133-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We demonstrate a physiological role for tumstatin, a cleavage fragment of the alpha3 chain of type IV collagen (Col IValpha3), which is present in the circulation. Mice with a genetic deletion of Col IVa3 show accelerated tumor growth associated with enhanced pathological angiogenesis, while angiogenesis associated with development and tissue repair are unaffected. Supplementing Coll IValpha3-deficient mice with recombinant tumstatin to a normal physiological concentration abolishes the increased rate of tumor growth. The suppressive effects of tumstatin require alphaVbeta3 integrin expressed on pathological, but not on physiological, angiogenic blood vessels. Mice deficient in matrix metalloproteinase-9, which cleaves tumstatin efficiently from Col IValpha3, have decreased circulating tumstatin and accelerated growth of tumor. These results indicate that MMP-generated fragments of basement membrane collagen can have endogenous function as integrin-mediated suppressors of pathologic angiogenesis and tumor growth.
引用
收藏
页码:589 / 601
页数:13
相关论文
共 76 条
[1]   Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome [J].
Andrews, KL ;
Mudd, JL ;
Li, C ;
Miner, JH .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (02) :721-730
[2]   Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].
Bergers, G ;
Brekken, R ;
McMahon, G ;
Vu, TH ;
Itoh, T ;
Tamaki, K ;
Tanzawa, K ;
Thorpe, P ;
Itohara, S ;
Werb, Z ;
Hanahan, D .
NATURE CELL BIOLOGY, 2000, 2 (10) :737-744
[3]   Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial [J].
Bramhall, SR ;
Hallissey, MT ;
Whiting, J ;
Scholefield, J ;
Tierney, G ;
Stuart, RC ;
Hawkins, RE ;
McCulloch, P ;
Maughan, T ;
Brown, PD ;
Baillet, M .
BRITISH JOURNAL OF CANCER, 2002, 86 (12) :1864-1870
[4]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[5]  
Colorado PC, 2000, CANCER RES, V60, P2520
[6]   Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome [J].
Cosgrove, D ;
Meehan, DT ;
Grunkemeyer, JA ;
Kornak, JM ;
Sayers, R ;
Hunter, WJ ;
Samuelson, GC .
GENES & DEVELOPMENT, 1996, 10 (23) :2981-2992
[7]   A secreted FGF-binding protein can serve as the angiogenic switch in human cancer [J].
Czubayko, F ;
LiaudetCoopman, EDE ;
Aigner, A ;
Tuveson, AT ;
Berchem, GJ ;
Wellstein, A .
NATURE MEDICINE, 1997, 3 (10) :1137-1140
[8]  
DERRY CJ, 1994, NEPHROL DIAL TRANSPL, V9, P355
[9]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174
[10]   Lack of type XV collagen causes a skeletal myopathy and cardiovascular defects in mice [J].
Eklund, L ;
Piuhola, J ;
Komulainen, J ;
Sormunen, R ;
Ongvarrasopone, C ;
Fässler, R ;
Muona, A ;
Ilves, M ;
Ruskoaho, H ;
Takala, TES ;
Pihlajaniemi, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (03) :1194-1199